Nektar Therapeutics grants Scott 4,000 stock options
The awards have different schedules: the RSUs vest in full one year following September 23, 2026, while the options vest monthly and expire September 22, 2034.
Rhea-AI Filing Summary
NEKTAR THERAPEUTICS director Greer R. Scott received grants of 2,000 restricted stock units (RSUs) and 4,000 stock options on September 23, 2026. The RSUs vest in full one year following September 23, 2026; the options vest in substantially equal monthly installments over the one-year period beginning September 23, 2026, have a $57.66 exercise price and expire September 22, 2034. The reported security amounts reflect the one-for-fifteen reverse stock split effected on June 8, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option F4 | 4,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1, F2, F3 | 2,000 | $0.00 | $0.00 |
Footnotes (4)
- F1. Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
- F2. This RSU award vests in full, one year following September 23, 2026.
- F3. On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
- F4. This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
Key Figures
Key Terms
restricted stock units financial
contingent right financial
vesting financial
Reverse Stock Split financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of NKTR's director's stock options?
AI-generated analysis. How Rhea-AI works. Not financial advice.